Washington, D.C., partner Jesse Witten spoke to the Bay Area Life Sciences Inhouse Lawyers Group on March 9, 2010, in Palo Alto, California. Jesse’s presentation, “Update on Federal Enforcement of MedTech Industry & Issues For Emerging companies,” covered recent government investigations and qui tam enforcement actions alleging off-label promotion, violations of the Anti-Kickback Statute and the Foreign Corrupt Practices Act, and failure to report adverse events, among other things. The group discussed issues of special significance to emerging companies, such as enforcement and compliance risks in the context of clinical trials and medical research.
Source: Bay Area Life Sciences Inhouse Lawyers Group